{"id":815612,"date":"2025-02-20T08:45:24","date_gmt":"2025-02-20T13:45:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/"},"modified":"2025-02-20T08:45:24","modified_gmt":"2025-02-20T13:45:24","slug":"grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/","title":{"rendered":"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ)"},"content":{"rendered":"
\n

PHILADELPHIA, Feb. 20, 2025 (GLOBE NEWSWIRE) — <\/p>\n

\n Akero Therapeutics, Inc. (NASDAQ: AKRO):<\/strong>\n <\/p>\n

Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company.<\/p>\n

\n If you have held Akero Therapeutics, Inc. (NASDAQ: AKRO) shares since prior to September 13, 2022, you can seek corporate reforms, the return of money back to the company, and a court approved monetary award at no cost to you whatsoever. You are encouraged to learn more about the investigation and your rights by visiting <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/akero-shareholder-investigation\/<\/strong>
\n <\/a>
\n . You can also contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n or call 267-507-6085.<\/strong>\n <\/p>\n

\n WHY:<\/strong> A recently filed underlying securities fraud class action Complaint alleges that Akero Therapeutics, via certain of its officers and directors, made false and\/or misleading statements and\/or failed to disclose to the investing public that: (i) approximately 20% of the patients enrolled in its SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study\u2019s design, materially influencing the study\u2019s potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient\u2019s cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.<\/p>\n

\n WHAT YOU CAN DO NOW<\/strong>: Current Akero shareholders who have held Akero shares since on or before <\/strong>September 13, 2022, <\/strong>can <\/strong>seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. <\/strong><\/p>\n

\n If you<\/strong>
\n would like to learn more about this matter, please <\/strong>
\n visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/akero-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n or call us at 267-507-6085.<\/strong> $AKRO #Akero<\/p>\n

\n Crocs, Inc. (NASDAQ: CROX): <\/strong>\n <\/p>\n

\n Current shareholders who acquired Crocs, Inc. (NASDAQ: CROX) shares prior to November 3, 2022, <\/strong>
\n can <\/strong>
\n seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever<\/strong>. You do not need to have lost money on your investment in order to participate. To learn more visit https:\/\/grabarlaw.com\/the-latest\/crocs-shareholder-investigation\/<\/a> or contact Joshua H. Grabar at jgrabar@grabarlaw.com<\/a>, <\/strong>or call us at 267-507-6085<\/strong>.<\/p>\n

\n WHY:<\/strong> Grabar Law Office is investigating claims on behalf of shareholders of Crocs, Inc. (NASDAQ: CROX). The investigation concerns whether certain officers and directors of Crocs breached their fiduciary duties.<\/p>\n

On February 17, 2022, Crocs acquired100% of the equity of a privately-owned casual footwear brand business (\u201cHEYDUDE\u201d), pursuant to a securities purchase agreement entered into on December 22, 2021. HEYDUDE is engaged in the business of distributing and selling casual footwear under the brand name \u201cHEYDUDE.\u201d The majority of HEYDUDE sales are currently in the United States.<\/p>\n

Croc\u2019s acquisition of HEYDUDE, is now at the center of a securities fraud class action complaint. According to the underlying class action complaint, it is alleged that Croc\u2019s, Inc. (NASDAQ: CROX), via certain of its officers and directors, made materially false and\/or misleading statements, as well as failed to disclose material adverse facts, about the Company\u2019s business and operations. Specifically, Defendants misrepresented and\/or failed to disclose: (1) the nature and sustainability of HEYDUDE\u2019s revenue growth by concealing that 2022 revenue growth was driven, in large part, by the Company\u2019s efforts to stock third-party wholesalers and retailers following the February 2022 acquisition of HEYDUDE; (2) that as the Company\u2019s retail partners began to destock this excess inventory, waning product demand further negatively impacted the Company\u2019s financial results; and (3) that, as a result, Defendants\u2019 representations about the Company\u2019s business, operations, and prospects were materially false and misleading and\/or lacked a reasonable basis.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong> Current Crocs shareholders who have held shares of the Company\u2019s stock since prior to November 3, 2022, can seek corporate reforms, the return of funds, and a court approved incentive award if appropriate.<\/p>\n

\n If you<\/strong>
\n would like to learn more at no cost to you, you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/crocs-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at jgrabar@grabarlaw.com<\/a>, or call us at 267-507-6085.<\/strong> $CROX #Crocs<\/p>\n

\n Extreme Networks, Inc. (NASDAQ: EXTR):<\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of Extreme Networks, Inc. (NASDAQ: EXTR) shareholders.\u00a0The investigation concerns whether certain officers of Extreme Networks have breached their fiduciary duties owed to the company.<\/p>\n

\n Shareholders who have held Extreme Networks, Inc. (NASDAQ: EXTR) stock<\/strong>
\n since on or before July 27, 2022<\/strong>
\n should visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/extreme-networks-shareholder-investigation\/<\/strong>
\n <\/a>. You <\/strong>can <\/strong>seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you. You do not need to have lost money on your investment. <\/strong><\/p>\n

\n WHY:<\/strong>\u00a0\u00a0 An underlying securities fraud class action complaint alleges that that Extreme Networks, through certain of its officers and directors, made false and\/or misleading statements and failed to disclose the following adverse facts pertaining to Extreme\u2019s business, operations, and financial condition: (a) that Extreme Networks was suffering from adverse client demand trends as its clients had ordered more product from Extreme than needed in the wake of the COVID-19 pandemic to avoid supply shortages and because of a lack of alternative sourcing options and thereby had cannibalized their purchasing needs; (b) that Extreme Networks was increasingly offsetting these adverse organic demand trends with the fulfillment of backlog orders in a manner that materially exceeded the proportion represented to investors; (c) that, as a result of (a)-(b), Extreme Networks was drawing down its backlog at a much faster rate than represented to investors; (d) that, as a result of (a)-(c), Extreme Networks\u2019 backlog was already decreasing and at a much quicker pace than the Company\u2019s statements to investors that backlog would only \u201cbegin to shrink\u201d in 4Q23 and it would be not until \u201cfiscal \u201826 when it really goes back to normal\u201d; (e) that, as a result of (a)-(d), Extreme Networks\u2019 backlog was not on track to continue increasing to $600 million; and (f) that, as a result of (a)-(e) above, Defendants had materially misrepresented Extreme Networks\u2019 organic demand, revenue growth, and market share gains as the fulfillment of Extreme\u2019s backlog masked a decline in organic demand and attendant revenues.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong> Current Extreme Networks shareholders who have held Extreme Networks shares since prior to July 27, 2022, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever<\/strong>.<\/p>\n

\n If you would like to learn more about this matter, you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/extreme-networks-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua H. Grabar at\u00a0<\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n
\n ,<\/u>
\n <\/strong>
\n or call us at 267-507-6085<\/strong>. $EXTR #ExtremeNetworks #EXTR<\/p>\n

\n Domino\u2019s Pizza Corp. (NASDAQ: DPZ):<\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of Domino\u2019s Pizza, Inc. (NASDAQ: DPZ) shareholders. The investigation concerns whether certain officers and directors of Domino\u2019s breached the fiduciary duties they owed to the company.<\/p>\n

\n If you are a current Domino\u2019s shareholder who purchased Domino\u2019s shares prior to December 7, 2023, <\/strong>
\n you can <\/strong>
\n seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>
\n Please <\/strong>
\n visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/dominos-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at\u00a0<\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n
\n ,<\/u>
\n <\/strong>
\n or call us at 267-507-6085<\/strong>\n <\/p>\n

\n WHY?<\/strong>\u00a0\u00a0 As alleged in a recently filed securities fraud class action complaint, Domino\u2019s Pizza, Inc. (NASDAQ: DPZ), through certain of its officers, made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the underlying complaint alleges Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) DPE, the Company’s largest master franchisee, was experiencing significant challenges with respect to both new store openings and closures of existing stores; (ii) as a result, Domino’s was unlikely to meet its own previously issued long-term guidance for annual global net store growth; (iii) accordingly, Domino’s business and\/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>\u00a0\u00a0 If you purchased Domino\u2019s shares prior to December 7, 2023 and still hold shares today, <\/strong>you are encouraged <\/strong>to visit <\/strong>https:\/\/grabarlaw.com\/the-latest\/dominos-shareholder-investigation\/<\/strong><\/a> contact Joshua Grabar at\u00a0<\/strong>jgrabar@grabarlaw.com<\/strong><\/a>,<\/u><\/strong> or call 267-507-6085. You may be able to <\/strong>seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong> #Dominos #DPZ $DPZ<\/p>\n

\n Attorney Advertising Disclaimer<\/a>\n <\/p>\n

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: \u00a0267-507-6085
Email: jgrabar@grabarlaw.com<\/a><\/p>\n

A photo accompanying this announcement is available at https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/095e26b5-da04-4598-8413-8cb47e60a6a7<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, Feb. 20, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you have held Akero Therapeutics, Inc. (NASDAQ: AKRO) shares since prior to September 13, 2022, you can seek corporate reforms, the return of money back to the company, and a court approved monetary award at no cost to you whatsoever. You are encouraged to learn more about the investigation and your rights by visiting https:\/\/grabarlaw.com\/the-latest\/akero-shareholder-investigation\/ . You can also contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085. WHY: A recently filed underlying securities fraud class action Complaint alleges that Akero Therapeutics, via certain of its officers and … <\/p>\n

Continue reading “Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815612","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGrabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Feb. 20, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you have held Akero Therapeutics, Inc. (NASDAQ: AKRO) shares since prior to September 13, 2022, you can seek corporate reforms, the return of money back to the company, and a court approved monetary award at no cost to you whatsoever. You are encouraged to learn more about the investigation and your rights by visiting https:\/\/grabarlaw.com\/the-latest\/akero-shareholder-investigation\/ . You can also contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085. WHY: A recently filed underlying securities fraud class action Complaint alleges that Akero Therapeutics, via certain of its officers and … Continue reading "Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T13:45:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ)\",\"datePublished\":\"2025-02-20T13:45:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/\"},\"wordCount\":1615,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/\",\"name\":\"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=\",\"datePublished\":\"2025-02-20T13:45:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/","og_locale":"en_US","og_type":"article","og_title":"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ) - Market Newsdesk","og_description":"PHILADELPHIA, Feb. 20, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (NASDAQ: AKRO): Grabar Law Office is investigating whether certain officers and directors of Akero breached their fiduciary duties owed to the company. If you have held Akero Therapeutics, Inc. (NASDAQ: AKRO) shares since prior to September 13, 2022, you can seek corporate reforms, the return of money back to the company, and a court approved monetary award at no cost to you whatsoever. You are encouraged to learn more about the investigation and your rights by visiting https:\/\/grabarlaw.com\/the-latest\/akero-shareholder-investigation\/ . You can also contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085. WHY: A recently filed underlying securities fraud class action Complaint alleges that Akero Therapeutics, via certain of its officers and … Continue reading \"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T13:45:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ)","datePublished":"2025-02-20T13:45:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/"},"wordCount":1615,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/","name":"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=","datePublished":"2025-02-20T13:45:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTgxMiM2NzYwNjAyIzIyMDEyNzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/grabar-law-office-is-investigating-claims-on-behalf-of-long-term-shareholders-of-akero-therapeutics-inc-nasdaq-akro-crocs-inc-nasdaq-crox-extreme-networks-inc-nasdaq-extr-and-domino\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Akero Therapeutics, Inc. (NASDAQ: AKRO); Crocs, Inc. (NASDAQ: CROX); Extreme Networks, Inc. (NASDAQ: EXTR); and Domino\u2019s Pizza Corp. (NASDAQ: DPZ)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815612"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815612\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}